Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Jim Tananbaum’s Foresite Capital Buys More Shares of Aerie Pharmaceuticals Inc (AERI)

A new 13G filing has been submitted to the SEC by Jim Tananbaum‘s Foresite Capital, in relation to the investor’s position in Aerie Pharmaceuticals Inc (NASDAQ:AERI). The filing reveals the latest share ownership information of all relevant parties and subsidiaries of the investor, which amounts to 1.37 million shares. Foresite Capital Fund II and III reported joint ownership of just over 970,000 shares as of the end of December. These 13G filings can prove invaluable to investors, as they show the latest moves made by top investors in stocks which they are or were very bullish on, and in a timely fashion in most cases. You can find the latest such filing embedded below and on the following pages.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Foresite Capital Fund II 844,240 844,240 844,240 3.2%
Foresite Capital Management II 844,240 844,240 844,240 3.2%
Foresite Capital Fund III 492,203 492,203 492,203 1.9%
Foresite Capital Management III 492,203 492,203 492,203 1.9%
James Tananbaum ( Tananbaum ) 1,336,443 1,336,443 1,336,443 5.1%
Jim Tananbaum
Jim Tananbaum
Foresite Capital

Page 1 of 11 SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. ___________)*

Aerie Pharmaceuticals, Inc.

(Name of
Issuer)

Common Stock

(Title of
Class of Securities)

00771V108

(CUSIP Number)

February 9, 2016

(Date of
Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

(Continued on following pages)

Page 1 of 11

Exhibit Index on Page 10

Follow Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Trade (NASDAQ:AERI) Now!
Loading...